Introduction {#s1}
============

Prescribing medicines is fundamental to the medical management of most long-term conditions. However, approximately half of this medication is not taken as directed, representing a failure to translate potentially effective treatment into optimal outcomes for patients and society [@pone.0080633-National1], [@pone.0080633-World1]. Where prescriptions are appropriate, this level of nonadherence has potentially serious consequences, both for individual patients, in terms of lost opportunities for health gain with increased morbidity and mortality [@pone.0080633-Simpson1], and for the health care system, in terms of wasted resources, increased use of services and hospital admissions [@pone.0080633-Horne1].

In the absence of a single definitive intervention to address nonadherence [@pone.0080633-Haynes1], the NICE Medicines Adherence Guidelines amalgamate insights from trials of interventions and explanatory studies of nonadherence [@pone.0080633-National1]. They apply a perceptions and practicalities approach [@pone.0080633-Horne1] recognising that nonadherence may be both unintentional and intentional. Unintentional nonadherence occurs when the patient wants to adhere but is unable to because they lack capacity or resources. For example, they may not have understood the instructions, cannot afford copayment costs, or find it difficult to schedule, administer or remember the treatment. Intentional nonadherence occurs when the patient decides not to follow the recommendations. It is best understood in terms of the perceptual factors (e.g. beliefs and preferences) influencing motivation to start and continue with treatment.

Prescribing consultations do not occur in a vacuum. Patients (and prescribers) bring pre-existing beliefs about the illness and treatment [@pone.0080633-Weinman1], [@pone.0080633-Horne2] which influence the patient's evaluation of the prescription, their adherence and even beneficial [@pone.0080633-Benedetti1] or adverse outcomes [@pone.0080633-Colloca1]. Interventions to optimise adherence tend to be more effective if they are tailored to the needs of the individual taking account of the perceptions of the treatment as well as practical abilities and resources that enable or impede their adherence [@pone.0080633-Horne3]. Although the perceptual and practical dimensions of adherence are influenced by the social, cultural, economic and healthcare system contexts, taking account of the patient's beliefs about the prescribed medication is fundamental to shared-decision making and supporting adherence [@pone.0080633-National1], [@pone.0080633-DeMaeseneer1].

Research conducted with patients with a variety of long-term conditions suggests that the key beliefs influencing patients' common-sense evaluations of prescribed medicines can be grouped under two categories: perceptions of personal need for treatment (Necessity beliefs) and Concerns about a range of potential adverse consequences [@pone.0080633-Horne2], [@pone.0080633-Horne4], [@pone.0080633-Horne5]. This 'Necessity-Concerns Framework (NCF)' potentially offers a convenient model for clinicians to elicit and address key beliefs underpinning patients' attitudes and decisions about treatment.

Over the past decade, a number of studies have been conducted, using a validated questionnaire, the Beliefs about Medicines Questionnaire [@pone.0080633-Horne6] to quantify Necessity beliefs and Concerns in order to explore the relationship between these beliefs and adherence. This research spans a range of long-term medical conditions, across different settings and within various cultural groups. Many of the individual studies have demonstrated the utility of the NCF in explaining nonadherence to medication (e.g. [@pone.0080633-Maidment1]--[@pone.0080633-Clatworthy1]). It is therefore timely that a meta-analysis is performed to consolidate the results from these studies and to examine the explanatory value of the NCF in predicting adherence to medication prescribed for long-term medical conditions. In line with the underlying theory, we hypothesized that adherence in long-term conditions would be associated with stronger perceptions of Necessity for treatment and fewer Concerns about adverse consequences.

Methods {#s2}
=======

This review was conducted in line with the MOOSE guidelines for meta-analysis of observational trials [@pone.0080633-Stroup1].

Literature Search {#s2a}
-----------------

A computerised literature search was conducted by the investigators on April 22^nd^, 2013 using EMBASE, Medline, PsycInfo, CDSR/DARE/CCT and CINAHL. The search strategy included the following terms:

**BMQ or belief\$**

***and***

treatment\$ ***or*** medicine\$ ***or*** medication\$

***and***

adheren\$ ***or*** complian\$

The search was limited to studies published from the year 1999 onwards (the year in which the BMQ was published). Duplicates were removed.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Identified studies were included in the meta-analysis if they met the following criteria:

1.  participants were suffering from a long-term condition

2.  participants were taking medication

3.  participants were adults

4.  the article was published in a peer-reviewed journal

5.  the Necessity and/or Concerns subscales of the BMQ were used

6.  a measure of adherence was employed

There were no restrictions based on language, or on cultural or geographical factors.

Titles and abstracts were screened for relevance, and the full text of relevant articles was obtained. Data from each article was extracted as described below.

Selection of Results When Multiple Relationships between Beliefs and Adherence Were Reported {#s2c}
--------------------------------------------------------------------------------------------

Fifteen studies reported multiple associations of beliefs related to different adherence measurements (details reported in [Table 1](#pone-0080633-t001){ref-type="table"}). Where the choice was between adherence measures, the most objective measure was selected for the meta-analysis. Therefore, electronic monitoring of adherence [@pone.0080633-Gonzalez1] and prescription redemption data [@pone.0080633-Byer1] were chosen over self-report. Where data was presented for both 'on demand' and prophylactic medications, data for the prophylactic medication data were chosen [@pone.0080633-deThurah1], [@pone.0080633-Llewellyn1], for consistency with medications prescribed for other long-term conditions. In studies where cross-sectional and longitudinal data were both available, longitudinal data was used within the analysis [@pone.0080633-deThurah1], [@pone.0080633-French1]--[@pone.0080633-Ovchinikova1]. Where one group provided cross-sectional data at multiple timepoints, the timepoint with the fewest missing data points was selected [@pone.0080633-Unni1]. If the choice was between two self report measures of adherence, we used the more commonly used measure. Thus the Morisky Medication Adherence Scale (MMAS) was chosen over the Brief Medication Questionnaire [@pone.0080633-Aikens1] and the ACTG adherence measure was used over the Walsh VAS scale [@pone.0080633-Johnson1]. Where patients within a sample were taking multiple medications and individual associations were provided for each medication [@pone.0080633-Batchelder1], [@pone.0080633-AllenLaPointe1], the mean association was used within the meta-analysis but individual effect sizes are reported in [Table 1](#pone-0080633-t001){ref-type="table"} to facilitate comparison. Where data on two samples are reported within the same study [@pone.0080633-Trachtenberg1], [@pone.0080633-Unni2] we included both associations within the analysis.
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###### Summary Data for Included Studies.

![](pone.0080633.t001){#pone-0080633-t001-1}

  Author and date                                                      Country                 Illness Group                 N     \% male                                                 Mean age (SD)                                                                          Study Design                                                                                                                           Adherence measure                                                                                                     BMQ (number of items)        *OR*      *p*
  ------------------------------------------------------------------- ---------- ----------------------------------------- ------ ---------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- -------- ---------
  Aakre et al.                                                           USA                     Comorbid                    44      45%                                                    51.1 (9.3)                                                                               Cross-                                                                                                                             1\) Brief Medication                                                                                                       Necessity (5)           1.467     0.523
  \(2012\) [@pone.0080633-Aakre1]                                                             Serious Mental                                                                                                                                                                        sectional                                                                                                                              Questionnaire                                                                                                           Concerns (6)            0.977     0.969
                                                                                             Illness and Type                                                                                                                                                                                                                                                                                                              (Antipsychotic                                                                                                          Necessity (5)           4.151     0.024
                                                                                                II Diabetes                                                                                                                                                                                                                                                                                                                 medication)                                                                                                            Concerns (6)            0.673     0.520
                                                                                                                                                                                                                                                                                                                                                                                                   2\) Brief Medication Questionnaire (Hypoglycaemic medication)                                                                                                                   
  Aflakseir                                                              IRN                      Type II                   102      22%                                                    40.7 (11.4)                                                                              Cross-                                                                                                                             MARS 10 item version                                                                                                       Necessity (5)           1.670     0.172
  \(2012\) [@pone.0080633-Aflakseir1]                                                            Diabetes                                                                                                                                                                           sectional                                                                                                                         see Barnes et al., 2004                                                                                                      Concerns (5)            0.169    \<0.001
  Aikens et al.                                                          USA                    Depression                   82      21%                                                   42.9 (10.63)                                                                              Cross-                                                                                                                          1\) General adherence: 4-                                                                                                     Necessity (5)           2.097     0.075
  \(2005\) [@pone.0080633-Aikens1]                                                                                                                                                                                                                                                  sectional                                                                                                                item MMAS[a](#nt102){ref-type="table-fn"}                                                                                             Concerns (5)            0.247     0.001
                                                                                                                                                                                                                                                                                                                                                                                                                      2\) Recent adherence: 3-                                                                                                     Necessity (5)           3.129     0.008
                                                                                                                                                                                                                                                                                                                                                                                                                item Brief Medication Questionnaire                                                                                                Concerns (5)            0.333     0.009
  Aikens & Piette                                                        USA                     Diabetes                   803      38%                                                    55.3 (11.8)                                                                              Cross-                                                                                                                                 Single item                                                                                                            Necessity (5)           1.430     0.069
  \(2009\) [@pone.0080633-Aikens3]                                                                                                                                                                                                                                                  sectional                                                                                                                                                                                                                                                      Concerns (6)            0.357    \<0.001
  Aikens &                                                               USA                    Depression                  163      38%                                                      35 (10)                                                                              Prospective                                                                                                                            Brief Medication                                                                                                         Necessity (5)           2.582     0.002
  Klinkman (2012) [@pone.0080633-Aikens4]                                                                                                                                                                                                                                                                                                                                                           Questionnaire AND STAR\*D Medication Adherence Questionnaire                                                                                   Concerns (5)            0.683     0.195
  Allen LaPointe                                                         USA                  Acute Coronary                972       6                                                    Medians for 6                                                                           Prospective                                                                                                                           Self-report of no                                                                                                         Necessity (5)           1.262     0.137
  et al. (2011) [@pone.0080633-AllenLaPointe1]                                                   Syndrome                           groups                                                    groups                                                                                                                                                                                                                    discontinuation nor                                                                                                        Concerns (5)            0.549    \<0.001
                                                                                                                                   in range                                                 between 56-                                                                                                                                                                                                                 missed doses in last                                                                                                       Necessity (5)           1.315     0.059
                                                                                                                                   66--74%                                                   61 SD not                                                                                                                                                                                                                 month for 1) ACEI/ARB;                                                                                                      Concerns (5)            0.546    \<0.001
                                                                                                                                                                                             reported                                                                                                                                                                                                                 2\) Beta-blocker and 3)                                                                                                      Necessity (5)           1.033     0.826
                                                                                                                                                                                                                                                                                                                                                                                                                       Lipid-lowering therapy                                                                                                      Concerns (5)            0.488    \<0.001
  Barnes et al.                                                           NZ                     Diabetes                    82      Not                                                   European 59.6                                                                             Cross-                                                                                                                            MARS plus two items re                                                                                                      Necessity (5)           4.054     0.001
  \(2004\) [@pone.0080633-Barnes1]                                                                                                 reported                                         (12.7); Tongan 59.2 (11.2)                                                                      sectional                                                                                                                             natural remedies                                                                                                         Concerns (5)            1.670     0.213
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Batchelder et al.                                                      USA                   Comorbid HIV                  62      45%                                                    52.8 (7.3)                                                                               Cross-                                                                                                                                5-item MARS 1)                                                                                                            Necessity             1.300     0.306
  \(2013\) [@pone.0080633-Batchelder1]                                                          and Type II                                                                                                                                                                         sectional                                                                                                                        Antiretroviral 2) Diabetes                                                                                                      Concerns              0.200     0.001
                                                                                                 Diabetes                                                                                                                                                                                                                                                                                                                    medication                                                                                                              Necessity             1.050     0.878
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Concerns Unspecified        0.450     0.041
  Beck et al.                                                            SWZ                   Schizophrenia                150     65.3%                                                   44.9 (11.7)                                                                              Cross-                                                                                                                             Medication adherence                                                                                                       Necessity (5)           1.942     0.029
  \(2011\) [@pone.0080633-Beck2]                                                        or Schizoaffective Disorder                                                                                                                                                                 sectional                                                    subscale of the Service Engagement Scale (Tait et al., 2002)- clinician rated. Brief Adherence Rating Scale (BARS; Byerly et al., 2008) BARS selected for use here                                Concerns (5)            0.775     0.396
  Berglund et al.                                                        SWE                   Statin Users                 414     50.8%                                                   64.2 (9.5)                                                                               Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           2.266    \<0.001
  \(2013\) [@pone.0080633-Berglund1]                                                                                                                                                                                                                                                sectional                                                                                                                                                                                                                                                      Concerns (5)            1.338     0.105
  Bhattacharya et                                                         UK                   Colorectal or                 43     44.2%                                                   64.5 (7.4)                                                                               Cross-                                                                                                                                 5-item MARS                                                                                                            Necessity (5)           1.408     0.562
  al. (2012) [@pone.0080633-Bhattacharya1]                                                     Breast Cancer                                                                                                                                                                        sectional                                                                                                                                                                                                                                                      Concerns (5)            0.570     0.352
  Brown et al.                                                           USA                    Depression                  192      29%                                                    45.2 (16.0)                                                                              Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           1.235     0.425
  \(2005\) [@pone.0080633-Brown2]                                                                                                                                                                                                                       sectional (Longitudinal study but only baseline results reported)                                                                                                                                                                                                                          Concerns (5)            0.362    \<0.001
  Brown et al. (2013) [@pone.0080633-Brown1]                             USA                        HIV                     116      58%                                                    45.3 (8.6)                                                                           Cross-sectional                                                                                VAS scale 0--100% used to rate adherence to each medication over the last month dichotomized at 95%                                                                Necessity (8)           2.357     0.014
  Butler et al.                                                           UK                       Renal                     58      66%                                                     48.0 (13)                                                                               Cross-                                                                                                             Electronic monitors[b](#nt103){ref-type="table-fn"}                                                                                        Necessity (5)           4.871     0.003
  \(2004\) [@pone.0080633-Butler1]                                                              Transplant                                                                                                                                                                          sectional                                                                                                                                                                                                                                                      Concerns (7)            0.517     0.184
  Byer & Myers                                                            UK                      Asthma                     64      50%                                                   39.6 (13.83)                                                                              Cross-                                                                                                                           1\) Number of preventer                                                                                                      Necessity (5)           5.915     0.001
  \(2000\) [@pone.0080633-Byer1]                                                                                                                                                                                                                                                    sectional                                                                                                                          inhaler prescriptions                                                                                                       Concerns (5)              --       --
                                                                                                                                                                                                                                                                                                                                                                                                             collected[a](#nt102){ref-type="table-fn"}                                                                                             Necessity (5)           3.129     0.05
                                                                                                                                                                                                                                                                                                                                                                                                                       2\) Number of reliever                                                                                                      Concerns (5)              --       --
                                                                                                                                                                                                                                                                                                                                                                                                                       inhaler prescriptions                                                                                                       Necessity (5)           5.915     0.001
                                                                                                                                                                                                                                                                                                                                                                                                                             collected                                                                                                             Concerns (5)              --       --
                                                                                                                                                                                                                                                                                                                                                                                                                    3\) Self-reported adherence                                                                                                                                    
  Byrne et al.                                                           IRE                  Coronary Heart                1084     65%                                                    66.0 (9.1)                                                                               Cross-                                                                                                                                 5-item MARS                                                                                                            Necessity (5)           2.551    \<0.001
  \(2005\) [@pone.0080633-Byrne1]                                                                 Disease                                                                                                                                                                           sectional                                                                                                                                                                                                                                                      Concerns (5)            0.669    \<0.001
  Chisholm-Burns                                                         USA                       Renal                    512     61.1%                                                   52.4 (10.7)                                                                              Cross-                                                                                                                              Immunosuppressant                                                                                                         Necessity (5)           2.065    \<0.001
  et al.                                                                                        Transplant                                                                                                                                                                          sectional                                                                                                                         Therapy Adherence Scale                                                                                                      Concerns (5)                    
  \(2012\) [@pone.0080633-ChisholmBurns2]                                                                                                                                                                                                                                                                                                                                                                            (ITAS) \<12 non-adherence                                                                                                                                     
  Clatworthy et al.                                                       UK                      Bipolar                   223      36%                                                     48 (11.2)                                                                               Cross-                                                                                                                                 5-item MARS                                                                                                            Necessity (5)           2.114     0.006
  \(2009\) [@pone.0080633-Clatworthy1]                                                           Disorders                                                                                                                                                                          sectional                                                                                                                                                                                                                                                      Concerns (6)            0.371     0.001
  Clifford et al.                                                         UK                  Chronic illness               146      52%                                                   64.3 (12.06)                                                                           Longitudinal                                                                                                                         Telephone call ("When                                                                                                       Necessity (5)           1.764     0.090
  \(2008\) [@pone.0080633-Clifford1]                                                                                                                                                                                                                                                                                                                  was the last time you missed a dose of this medicine?"). Nonadherence defined as any dose missed in the previous 7 days[b](#nt103){ref-type="table-fn"}                                      Concerns (5)            0.457     0.020
  Cooper et al.,                                                          UK                        HIV                     234      84%                                                     42 (8.9)                                                                             Longitudinal                                                                                                                           At 48 weeks MASRI                                                                                                        Necessity (15)           1.863     0.010
  \(2011\) [@pone.0080633-Cooper1]                                                                                                                                                                                                                                                                                                                                                          (Walsh et al., 2002) scale- VAS % taken over last month dichotomized at 95%                                                                            Concerns (8)            0.499     0.004
  de Boer-van der                                                        NTL                        HIV                     341      90%                                                        45                                                                                   Cross-                                                                                                                               Self report % of                                                                                                         Necessity (8)           1.600     0.018
  Kolk et al. (2008) [@pone.0080633-deBoervanderKolk1]                                                                                                                                                                                                                              sectional                                                                                                                        prescribed medicines taken                                                                                                    Concerns (11)           0.070     0.075
  De Las Cuevas                                                          ESP                     Affective                  167     23.4%                                                   56.1 (12.3)                                                                              Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           1.111     0.710
  et al. (2013) [@pone.0080633-DeLasCuevas1]                                                     Disorders                                                                                                                                                                          sectional                                                                                                                                                                                                                                                      Concerns (5)            2.521     0.002
  De Smedt et al.                                                        NTL                   Heart Failure                960     63.6%                                                   69.6 (11.9)                                                                              Cross-                                                                                                                             SECope non-adherence                                                                                                       Necessity (5)           1.257     0.616
  \(2012\) [@pone.0080633-DeSmedt1]                                                                                                                                                                                                                                                 sectional                                                                                                                   subscale (Johnson & Neilands, 2007)                                                                                                Concerns (5)            0.484     0.112
  de Thurah et al.                                                       DMK                    Rheumatoid                   91      36%                                                     Median 63                                                                             Prospective                                                                                                                          CQ-R 1) 9 months 2)                                                                                                        Necessity (5)           9.600    \<0.001
  \(2010\) [@pone.0080633-deThurah1]                                                             Arthritis                                                                                                                                                                                                                                                                                                                    baseline                                                                                                             Concerns (5)            0.420     0.132
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Necessity (5)           3.630     0.016
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Concerns (5)            0.793     0.652
  Ediger et al                                                           CAN                        IBD                     326      40%                                                   41.0 (14.06)                                                                              Cross-                                                                                                                 5-item MARS[b](#nt103){ref-type="table-fn"}                                                                                            Necessity (5)           1.522     0.039
  \(2007\) [@pone.0080633-Ediger1]                                                                                                                                                                                                                                                  sectional                                                                                                                                                                                                                                                      Concerns (5)            0.677     0.054
  Emilsson et al.                                                        SWE                      Asthma                     35     28.6%                                                   52.9 (14.7)                                                                              Cross-                                                                                                                                  Pill count                                                                                                            Necessity (5)           4.438     0.032
  \(2011\) [@pone.0080633-Emilsson1]                                                                                                                                                                                                                                                sectional                                                                                                                                                                                                                                                      Concerns (5)            0.555     0.365
  Fawzi et al.                                                           EGT                   Depression or                108     33.3%                                                   61.3 (5.3)                                                                               Cross-                                                                                                                                 10-item MARS                                                                                                           Necessity (5)           3.712     0.001
  \(2012\) [@pone.0080633-Fawzi1]                                                 Adjustment Disorder with Depressed Mood                                                                                                                                                           sectional                                                                                              (Thompson et al., 2000) MARS chosen and GAM (global adherence measure- 1 item)                                                                          Concerns (5)            0.269     0.001
  Foo et al.                                                             SGP                     Glaucoma                   344     64.8%                                                   66.1 (10.2)                                                                              Cross-                                                                                                                            8-item MMAS dichot. at                                                                                                      Necessity (4)           1.045     0.837
  \(2012\) [@pone.0080633-Foo1]                                                                                                                                                                                                                                                     sectional                                                                                                                                    8                                                                                                                 Concerns (5)            2.778    \<0.001
  French et al.                                                           UK                      Type II                   453     57.4%                                                    65.9 (10)                                                                             Prospective                                                                                                                        5-item MARS 1) Baseline                                                                                                      Necessity (5)           1.295     0.232
  \(2013\) [@pone.0080633-French1]                                                               Diabetes                                                                                                                                                                                                                                                                                                                 2\) Prospective                                                                                                          Concerns (5)            0.525     0.004
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Necessity (5)           1.800     0.013
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Concerns (5)            0.116    \<0.001
  Gauchet et al.                                                         FRA                        HIV                     127      78%                                                    39.7 (9.2)                                                                               Cross-                                                                                                                             16-item self-report                                                                                                        Necessity (5)           3.264     0.001
  \(2007\) [@pone.0080633-Gauchet1]                                                                                                                                                                                                                                                 sectional                                                                                                                       measure (devised by authors)                                                                                                   Concerns (5)            0.865     0.656
  Gatti et al.                                                           USA                  Chronic illness               275      27%                                                        \-                                                                                   Cross-                                                                                                                            8-item MMAS dichot. at                                                                                                      Necessity (5)           1.239     0.331
  \(2009\) [@pone.0080633-Gatti1]                                                                                                                                                                                                                                                   sectional                                                                                                                                    1                                                                                                                 Concerns (6)            0.357    \<0.001
  George &                                                               CAN                   Heart Failure                350      69%                                                    61.0 (12.6)                                                                              Cross-                                                                                                                         1\) Prescription dispensing                                                                                                    Necessity (5)                   
  Shalansky                                                                                                                                                                                                                                                                         sectional                                                                                                                            data (nonadherence                                                                                                        Concerns (5)            1.529     0.069
  \(2007\) [@pone.0080633-George1]                                                                                                                                                                                                                                                                                                                                     defined as \<90% mean refill adherence)[b](#nt103){ref-type="table-fn"}2) 4-item MMAS[c](#nt104){ref-type="table-fn"}                                                                               0.954     0.839
  Gonzalez et al.                                                        USA                        HIV                     325      60%                                                    40.9 (8.5)                                                                            Longitudinal                                                                                                                                1\) ACTG                                                                                                             Necessity (8)           1.494     0.048
  \(2007\) [@pone.0080633-Gonzalez1]                                                                                                                                                                                                                                               randomised                                                                                                                         2\) MEMS cap -- one drug                                                                                                     Concerns (11)           0.459    \<0.001
                                                                                                                                                                                                                                                                                      trial                                                                                                                            in each participant's                                                                                                       Necessity (8)           1.494     0.048
                                                                                                                                                                                                                                                                                                                                                                                  regimen monitored, usually the protease inhibitor (% adherence)[a](#nt102){ref-type="table-fn"}                                                                  Concerns (11)           0.720     0.106
  Griva et al.                                                            UK                      Kidney                    218     59.6%                                                   49.7 (12.3)                                                                              Cross-                                                                                                                            5-item MARS item plus                                                                                                       Necessity (5)           7.278    \<0.001
  \(2012\) [@pone.0080633-Griva1]                                                               Transplant                                                                                                                                                                          sectional                                                                                                                  serum immunosuppressant concentrations                                                                                              Concerns (5)                    
  Grunfeld et al                                                          UK                   Breast Cancer                110       0%                                                    56.3 (7.0)                                                                               Cross-                                                                                                            1\) Asked "In the past[c](#nt104){ref-type="table-fn"}                                                                                      Necessity (5)           2.916     0.007
  \(2005\) [@pone.0080633-Grunfeld1]                                                                                                                                                                                                                                                sectional                                                                                  week have you taken your tamoxifen everyday?" (Yes/No)[b](#nt103){ref-type="table-fn"} 2) 5-item MARS                                                               Concerns (5)            0.868     0.708
  Hedenrud et al.                                                        SWE                     Migraine                   174      16%                                                  Not calculable                                                                             Cross-                                                                                                                 5-item MARS[b](#nt103){ref-type="table-fn"}                                                                                            Necessity (5)           0.747     0.309
  \(2008\) [@pone.0080633-Hedenrud1]                                                                                                                                                                                                                                                sectional                                                                                                                                                                                                                                                      Concerns (5)            0.588     0.064
  Horne et al.                                                            UK                    Cardiac and                 210      49%                                                    50.8 (16.2)                                                                              Cross-                                                                                                                                  4-item RAM                                                                                                            Necessity (5)           2.018     0.006
  \(1999\) [@pone.0080633-Horne6]                                                      General Medical (pooled data)                                                                                                                                                                sectional                                                                                                                                                                                                                                                      Concerns (5)            0.347    \<0.001
  Horne &                                                                 UK                   Asthma, Renal                324      54%                                                   54.1 (15.96)                                                                              Cross-                                                                                                                                 4-item MARS                                                                                                            Necessity (5)           2.180    \<0.001
  Weinman (1999) [@pone.0080633-Horne2]                                               Cardiac, Oncology (pooled data)                                                                                                                                                               sectional                                                                                                                                                                                                                                                      Concerns (5)            0.281    \<0.001
  Horne et al.                                                            UK                       Renal                     47      49%                                                    49.0 (17.3)                                                                              Cross-                                                                                                                           Single item: 'How often                                                                                                      Necessity (5)           1.115     0.842
  \(2001\) [@pone.0080633-Horne13]                                                            (Haemodialysis)                                                                                                                                                                       sectional                                                                                                             do you deliberately miss a dose of medication?'                                                                                          Concerns (5)            0.215     0.010
  Horne &                                                                 UK                      Asthma                    100      39%                                                    49.3 (18.1)                                                                              Cross-                                                                                                                                 9-item MARS                                                                                                            Necessity (6)           3.405     0.002
  Weinman                                                                                                                                                                                                                                                                           sectional                                                                                                                                                                                                                                                      Concerns (11)           0.178    \<0.001
  \(2002\) [@pone.0080633-Horne11]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Horne et al.                                                            UK                        HIV                     109      97%                                                    41.2 (9.0)                                                                               Cross-                                                                                                                            Single item: 'How much                                                                                                      Necessity (8)           1.773     0.126
  \(2004\) [@pone.0080633-Horne14]                                                                                                                                                                                                                                                  sectional                                                                          of your HAART medication did you take within two hours of when you were supposed to?'[b](#nt103){ref-type="table-fn"}                                                       Concerns (11)           0.524     0.095
  Horne et al.                                                            UK                        HIV                     117      96%                                                    37.8 (8.4)                                                                             Prospective                                                                                                                         Single item: VAS from                                                                                                       Necessity (6)           2.477     0.008
  \(2007\) [@pone.0080633-Horne15]                                                                                                                                                                                                                                                  follow-up                                                                                                                  MASRI[b](#nt103){ref-type="table-fn"}                                                                                               Concerns (7)            0.298    \<0.001
  Horne et al.                                                            UK                        IBD                     1871     37%                                                     50 (16.0)                                                                               Cross-                                                                                                                                 4-item MARS                                                                                                            Necessity (8)           1.790    \<0.001
  \(2009\) [@pone.0080633-Horne12]                                                                                                                                                                                                                                                  sectional                                                                                                                                                                                                                                                      Concerns (9)            0.600    \<0.001
  Horne et al.                                                            UK                   Hypertension                 230      88%                                                       67.6                                                                                Prospective                                                                                                                           1\) 6- item MARS--                                                                                                        Necessity (5)           1.675     0.096
  \(2010\) [@pone.0080633-Horne7]                                                                                                                                                                                                                                                                                                                                                                                             baseline                                                                                                             Concerns (6)            0.464     0.013
                                                                                                                                                                                                                                                                                                                                                                                                                          2\) 6-item MARS                                                                                                          Necessity (5)           1.007     0.987
                                                                                                                                                                                                                                                                                                                                                                                                      Prospective (Compared to tablet count for 48% of sample)                                                                                     Concerns (6)            0.195    \<0.001
  Hou et al.                                                              UK                      Bipolar                    35     28.6%                                                     45 (11)                                                                                Cross-                                                                                                                           MMAS 4-item (dichot. at                                                                                                      Necessity (5)           0.881     0.837
  \(2010\) [@pone.0080633-Hou1]                                                             Affective Disorder                                                                                                                                                                      sectional                                                                                                                                   1\)                                                                                                                Concerns (5)            0.680     0.532
  Hunot et al.                                                            UK                    Depression                  178      25%                                                    40.1 (12.6)                                                                           Longitudinal                                                                                                                        1\) Single item: current                                                                                                     Necessity (5)           3.346    \<0.001
  \(2007\) [@pone.0080633-Hunot1]                                                                                                                                                                                                                                                                                           antidepressant use/non-use ("Are you currently taking antidepressants?")[b](#nt103){ref-type="table-fn"} 2) MARS[c](#nt104){ref-type="table-fn"} 3) Prescription refill data[c](#nt104){ref-type="table-fn"}           Concerns (6)            0.223    \<0.001
  Iihara et al                                                           JPN                     Hospital                   151     62.3%                                                       --                                                                                   Cross-                                                                                                                            Measure based on MMAS                                                                                                       Necessity (5)           1.998     0.020
  \(2010\) [@pone.0080633-Iihara1]                                                              Inpatients                                                                                                                                                                          sectional                                                                                                                                                                                                                                                      Concerns (5)            0.593     0.079
  Johnson et al.                                                         USA                        HIV                     295      100%                                                   45.2 (10.1)                                                                              Cross-                                                                                                                              1\) ACTG 3 days (%                                                                                                        Necessity (5)           0.960     0.365
  \(2012\) [@pone.0080633-Johnson1]                                                                                                                                                                                                                                                 sectional                                                                                                          taken) dichot. at 100%[a](#nt102){ref-type="table-fn"}                                                                                      Concerns (5)            0.930     0.058
                                                                                                                                                                                                                                                                                                                                                                                                                       2\) Walsh VAS 0--100%                                                                                                       Necessity (5)           1.020     0.572
                                                                                                                                                                                                                                                                                                                                                                                                                    last 30 days dichot at 100%                                                                                                    Concerns (5)            0.960     0.273
  Jonsdottir et al.                                                       UK                  Schizophrenia/                280      51%                                                       35.1                                                                                  Cross-                                                                                                                                VAS (0%--100%)                                                                                                          Necessity (8)           5.887    \<0.001
  \(2009\) [@pone.0080633-Jnsdttir1]                                                         Bipolar disorder                                                                                                                                                                       sectional                                                                                                                                                                                                                                                      Concerns (9)            0.493     0.057
  Kemp et al.                                                             UK                     Epilepsy                    37      51%                                                   40.7 (SD not                                                                              Cross-                                                                                                                                 Low-dose of                                                                                                            Necessity (5)           0.441     0.200
  \(2007\) [@pone.0080633-Kemp1]                                                                                                                                                             reported)                                                                              sectional                                                                                        phenobarbital indicative of nonadherence, and/or measurement of antiepileptic drug levels                                                                     Concerns (5)            0.599     0.414
  Khanderia et al.                                                       USA                  Coronary Artery               132      83%                                                    65.8 (10.1)                                                                              Cross-                                                                                                                 4-item MMAS[b](#nt103){ref-type="table-fn"}                                                                                            Necessity (5)           1.050     0.875
  \(2008\) [@pone.0080633-Khanderia1]                                                          Bypass Graft                                                                                                                                                                         sectional                                                                                                                                                                                                                                                      Concerns (5)            0.584     0.092
  Kressin et al.                                                         USA                   Hypertension                 806      35%                                                        59                                                                                   Cross-                                                                                                                           Hill-Bone Compliance to                                                                                                      Necessity (5)           1.414     0.200
  \(2010\) [@pone.0080633-Kressin1]                                                                                                                                                                                                                                                 sectional                                                                                                       High Blood Pressure Therapy Scale, 9 item adherence subscale                                                                                   Concerns (5)            0.525    \<0.001
  Kronish et al                                                          USA                   Stroke or TIA                600     60.6%                                                   63.4 (11.2)                                                                              Cross-                                                                                                                            8-item MMAS dichot. at                                                                                                      Necessity (5)           1.120     0.557
  \(2013\) [@pone.0080633-Kronish1]                                                                                                                                                                                                                                                 sectional                                                                                                                                  \> = 6                                                                                                      Concerns (4) (modified items)   0.193    \<0.001
  Kung et al.                                                             NZ                   Heart, Liver,                326     64.4%                                                      Heart                                                                                 Cross-                                                                                                                              Immunosuppressant                                                                                                         Necessity (5)           1.605     0.021
  \(2012\) [@pone.0080633-Kung1]                                                              Lung Transplant                                            transplant: 54.4 (11.8) Lung transplant 49.3 (13.1) Liver transplant 55.1 (12.3)                                           sectional                                                                                                            Therapy Adherence Scale (ITAS) \<12 non-adherence                                                                                         Concerns (5)            0.493     0.001
  Llewellyn                                                               UK                    Haemophilia                  65      100%                                                   36.4 (12.2)                                                                              Cross-                                                                                                                               1\) Adherence to                                                                                                         Necessity (5)           5.915     0.001
  et al. (2003) [@pone.0080633-Llewellyn1]                                                                                                                                                                                                                                          sectional                                                                                                                        frequency of prophylactic                                                                                                     Concerns (5)            0.599     0.270
                                                                                                                                                                                                                                                                                                                                                                                                                       infusion with clotting                                                                                                      Necessity (5)           4.241     0.004
                                                                                                                                                                                                                                                                                                                                     factor[a](#nt102){ref-type="table-fn"} 2) Adherence to recommended 'on demand' dose of clotting factor 3) Adherence to recommended dose of clotting factor[c](#nt104){ref-type="table-fn"}                    Concerns (5)            0.897     0.813
  Maguire et al.                                                          UK                   Hypertension                 327      46%                                                   Not reported                                                                              Cross-                                                                                                                                  4-item RAM                                                                                                            Necessity (5)           0.665     0.242
  \(2008\) [@pone.0080633-Maguire1]                                                                                                                                                                                                                                                 sectional                                                                                                                                                                                                                                                      Concerns (5)            0.422     0.014
  Mahler et al.                                                          GMY                   Mixed Chronic                360     53.3%                                                 69.5 range 19--                                                                            Cross-                                                                                                                                5-item MARS D                                                                                                           Necessity (5)           2.097    \<0.001
  \(2012\) [@pone.0080633-Mahler1]                                                                Illness                                                                                       95                                                                                  sectional                                                                                                                                                                                                                                                      Concerns (5)            0.515     0.001
  Maidment                                                                UK                    Depression                   67      49%                                                    74.2 (6.1)                                                                               Cross-                                                                                                                               Global Adherence                                                                                                         Necessity (5)           3.002     0.020
  et al. (2002) [@pone.0080633-Maidment1]                                                     (older adults)                                                                                                                                                                        sectional                                                                                                                  Measure (single rating by interviewer)                                                                                              Concerns (5)            0.247     0.004
  Menckeberg et                                                          NTL                      Asthma                    238      33%                                                    36.2 (6.3)                                                                               Cross-                                                                                                                                 5-item MARS                                                                                                            Necessity (9)           3.878    \<0.001
  al. (2008) [@pone.0080633-Menckeberg1]                                                                                                                                                                                                                                            sectional                                                                                                                                                                                                                                                      Concerns (12)           0.496     0.004
  Moshkovska et                                                           UK                    Ulcerative                  169      51%                                                    49 (SD not                                                                               Cross-                                                                                                                          1\) 12 item study specific                                                                                                    Necessity (5)           1.976     0.002
  al. (2009) [@pone.0080633-Moshkovska3]                                                          Colitis                                                                                    reported)                                                                              sectional                                                                                                                        self report questionnaire                                                                                                     Concerns (6)            0.639     0.035
  Nakhutina et al.                                                       USA                     Epilepsy                    72     37.5%                                                    44 (14.2)                                                                               Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           1.388     0.455
  \(2011\) [@pone.0080633-Nakhutina1]                                                                                                                                                                                                                                               sectional                                                                                                                                                                                                                                                      Concerns (5)            0.694     0.406
  Neame &                                                                 UK                    Rheumatoid                  344      33%                                                    49.5% aged                                                                               Cross-                                                                                                                           Single item: 'I often do                                                                                                     Necessity (5)           0.885     0.737
  Hammond (2005) [@pone.0080633-Neame1]                                                          Arthritis                                                                                    over 65                                                                               sectional                                                                                                    not take my medicines as directed'[b](#nt103){ref-type="table-fn"}                                                                                Concerns (5)            0.313     0.002
  Nicklas et al.                                                          UK                   Chronic Pain                 217       --                                                        --                                                                                   Cross-                                                                                                                                 6-item MARS                                                                                                            Necessity (5)           2.018     0.005
  \(2010\) [@pone.0080633-Nicklas1]                                                                                                                                                                                                                                                 sectional                                                                                                                                                                                                                                                      Concerns (5)            0.645     0.079
  O'Carroll et al.                                                        UK                       Liver                     33      52%                                                   55.8 (13.37)                                                                              Cross-                                                                                                                          1\) 'Medication adherence'                                                                                                    Necessity (5)           1.734     0.411
  \(2006\) [@pone.0080633-OCarroll3]                                                            Transplant                                                                                                                                                                          sectional                                                                                   factor of the Transplant Effects Questionnaire (TxEQ) 2) 5-item MARS[c](#nt104){ref-type="table-fn"}                                                               Concerns (5)            0.137     0.009
  O'Carroll et al.                                                        UK                     Ischaemic                  180      54%                                                     69 (11.4)                                                                               Cross-                                                                                                                               5-item MARS with                                                                                                         Necessity (5)           0.705     0.202
  \(2011\) [@pone.0080633-OCarroll1]                                                              Stroke                                                                                                                                                                            sectional                                                                                                                        salicyclic acid/creatinine                                                                                                    Concerns (5)            0.209    \<0.001
                                                                                                                                                                                                                                                                                                                                                                                                                            1\) Baseline                                                                                                           Necessity (5)           0.778     0.359
                                                                                                                                                                                                                                                                                                                                                                                                                          2\) Prospective                                                                                                          Concerns (5)            0.328    \<0.001
  Ovchinikova et                                                         AUS                      Asthma                    134      31%                                                      53 (19)                                                                             Longitudinal                                                                                                                          MARS 1) Baseline 2)                                                                                                        Necessity (5)           1.429     0.262
  al. (2011) [@pone.0080633-Ovchinikova1]                                                                                                                                                                                                                                                                                                                                                                                   Prospective                                                                                                            Concerns (5)            0.220    \<0.001
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Necessity (5)           1.328     0.387
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Concerns (5)            0.278    \<0.001
  Percival et                                                            AUS                   Heart Failure                 43     83.7%                                                   64.2 (17.1)                                                                              Cross-                                                                                                                            5-item MARS dichot. at                                                                                                      Necessity (5)           3.068     0.165
  al.(2012) [@pone.0080633-Percival1]                                                                                                                                                                                                                                               sectional                                                                                                                                    23                                                                                                                Concerns (5)            0.508     0.399
  Peters et al.                                                          USA                      Marfan                    174      42%                                                    39.8 (12.2)                                                                              Cross-                                                                                                                          3-item self-report measure                                                                                                    Necessity (5)           1.299     0.417
  \(2001\) [@pone.0080633-Peters1]                                                               Syndrome                                                                                                                                                                           sectional                                                                                                                           (adapted from MARS)                                                                                                        Concerns (5)            0.424     0.010
  Phatak &                                                               USA                   Hypertension,                250      38%                                                   \<30 (11.2%)                                                                              Cross-                                                                                                                                 9-item MMAS                                                                                                            Necessity (5)           1.550     0.059
  Thomas                                                                                      Arthritis, Back                                                                              30--39 (14%)                                                                             sectional                                                                                                                                                                                                                                                      Concerns (6)            0.215    \<0.001
  \(2006\) [@pone.0080633-Phatak1]                                                               Problems,                                                                                40--49 (37.2%)                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                  Asthma,                                                                                 50--59 (24.4%)                                                                                                                                                                                                                                                                                                                                                                           
                                                                                           Hypercholesterolemia                                                                            \>60 (13.2%)                                                                                                                                                                                                                                                                                                                                                                            
  Rajpura &                                                              USA                   Hypertension                 117     64.1%                                                 55--65 (23.9%)                                                                             Cross-                                                                                                                                     MMAS                                                                                                               Necessity (5)           2.551     0.008
  Nayak (2013)                                                                              and aged 55 or over                                                                            \>65 (52.1%)                                                                             sectional                                                                                                                                                                                                                                                      Concerns (5)            0.423     0.014
  Rees et al.                                                            AUS                     Glaucoma                   131     61.1%                                                   67.7 (13.6)                                                                              Cross-                                                                                                                                  4-item RAM                                                                                                            Necessity (5)           1.966     0.035
  \(2010\) [@pone.0080633-Rees1]                                                                                                                                                                                                                                                    sectional                                                                                                                                                                                                                                                      Concerns (8)            0.651     0.180
  Rees et al.                                                            USA,                    Glaucoma                   475     55.4%                                                     African                                                                                Cross-                                                                                                                                  4-item RAM                                                                                                            Necessity (5)           2.385    \<0.001
  \(2013\) [@pone.0080633-Rees2]                                       SGP, AUS                                                               Americans: 69.6 (12.4) White Americans: 68.65 (13.0) Australians: 69.2 (13.1) Singaporeans: 65.1 (11.8)                               sectional                                                                                                                                                                                                                                                      Concerns (8)            0.414    \<0.001
  Reynolds et al                                                         USA                   Osteoporosis                 193       0%                                                                                                                                             Cross-                                                                                                                           Osteoporosis Specific 8-                                                                                                     Necessity (5)           3.405    \<0.001
  \(2012\) [@pone.0080633-Reynolds1]                                                                                                                                                                                                                                                sectional                                                                                                                                item MMAS                                                                                                             Concerns (6)            0.424     0.005
  Ross et al.                                                             UK                   Hypertension                 515      52%                                                   59.9 (12.16)                                                                              Cross-                                                                                                                 4-item MMAS[b](#nt103){ref-type="table-fn"}                                                                                            Necessity (5)           3.060     0.001
  \(2004\) [@pone.0080633-Ross1]                                                                                                                                                                                                                                                    sectional                                                                                                                                                                                                                                                      Concerns (5)                    
  Ruppar et al.                                                                                Hypertension                  33      21%                                                    70.6 (9.1)                                                                             Prospective                                                                                                                         MEMS for 6 weeks post-                                                                                                      Necessity (5)           0.501     0.306
  \(2012\) [@pone.0080633-Ruppar1]                                                                                                                                                                                                                                                                                                                                                                                              BMQ                                                                                                                Concerns (5)            0.254     0.053
  Russell &                                                               NZ                    Depression                   85      28%                                                    43.7 (11.5)                                                                              Cross-                                                                                                                                 5-item MARS                                                                                                            Necessity (5)           1.115     0.786
  Kazantzis (2008) [@pone.0080633-Russell1]                                                                                                                                                                                                                                         sectional                                                                                                                                                                                                                                                      Concerns (14)           0.269     0.002
  Schoenthaler et                                                        USA                      Type II                   608      48%                                                    62.1 (9.2)                                                                               Cross-                                                                                                                            MPR over last 2 years                                                                                                       Necessity (5)           0.757     0.060
  al. (2012) [@pone.0080633-Schoenthaler1]                                                       Diabetes                                                                                                                                                                           sectional                                                                                                                                                                                                                                                      Concerns (5)            0.878     0.380
  Schuz et al.                                                           GMY                   Older Adults                 309     59.3%                                                   73.3 (5.1)                                                                            Longitudinal                                                                                                                            2 items from RAM                                                                                                         Necessity (2)           1,353     0.155
  \(2011\) [@pone.0080633-Schuz2]                                                         with Comorbid Illnesses                                                                                                                                                                                                                                                                                                                                                                                                                                  Concerns (2)            0.590     0.014
  Shiyanbola &                                                           USA                     Diabetes                    16       0%                                                    46.1 (10.2)                                                                              Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           0.917     0.931
  Nelson (2011) [@pone.0080633-Shiyanbola3]                                                                                                                                                                                                                                         sectional                                                                                                                                                                                                                                                      Concerns (5)            1.539     0.671
  Sirey et al.                                                           USA                   Older Adults                 299     22.1%                                                   Nonadherent                                                                              Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           1.182     0.435
  \(2013\) [@pone.0080633-Sirey1]                                                         with Comorbid Illnesses                                                                 75.6 (7.3); Adherent 76.7 (7.4)                                                                   sectional                                                                                                                                                                                                                                                      Concerns (5)            0.494     0.001
  Sofianou et al.                                                        USA                      Asthma                    242     16.1%                                                   67.4 (6.8)                                                                               Cross-                                                                                                                                 10-item MARS                                                                                                           Necessity (5)           2.353    \<0.001
  \(2012\) [@pone.0080633-Sofianou1]                                                                                                                                                                                                                                                sectional                                                                                                                                                                                                                                                      Concerns (5)            0.437     0.001
  Tibaldi et al.,                                                       Italy                 Chronic illness               427      45%                                                      59 (14)                                                                                Cross-                                                                                                                                 5-item MARS                                                                                                            Necessity (5)           1.314     0.123
  \(2009\) [@pone.0080633-Tibaldi1]                                                                                                                                                                                                                                                 sectional                                                                                                                                                                                                                                                      Concerns (6)            0.488    \<0.001
  Sud et al.,                                                            USA                  Acute Coronary                208     60.6%                                                   64.9 (13.0)                                                                              Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           1.800     0.022
  \(2005\) [@pone.0080633-Sud1]                                                                  Syndrome                                                                                                                                                                           sectional                                                                                                                                                                                                                                                      Concerns (5)            0.720     0.198
  Trachtenberg et                                                      USA, UK                  Thalassemia                 371     47.4%                                                   24.0 (12.6)                                                                           Longitudinal                                                                                                                        Self-reported number of                                                                                                      Necessity (5)           0.694     0.256
  al. (2012) [@pone.0080633-Trachtenberg1]                                                                                                                                                                                                                                                                                                                                                                            doses taken in the past                                                                                                      Concerns (5)            0.964     0.910
                                                                                                                                                                                                                                                                                                                                                                                                                       week and month 1) DFO                                                                                                       Necessity (5)           1.115     0.633
                                                                                                                                                                                                                                                                                                                                                                                          2\) Oral iron chelator; serum ferritin, liver biopsy, liver iron concentration.                                                                          Concerns (5)            0.720     0.152
  Treharne et al.                                                         UK                    Rheumatoid                   85      25%                                                   58.9 (12.64)                                                                              Cross-                                                                                                                               1\) 19-item CQR                                                                                                          Necessity (5)           31.758   \<0.001
  \(2004\) [@pone.0080633-Treharne1]                                                             Arthritis                                                                                                                                                                          sectional                                                                                                        2\) 2 items from the MARS[c](#nt104){ref-type="table-fn"}                                                                                     Concerns (5)            0.621     0.239
  Unni & Farris                                                          USA                    Cholesterol                 420     54.4%                                                  Cholesterol:                                                                              Cross-                                                                                                                             Medication Adherence                                                                                                       Necessity (5)           0.981     0.925
  (2011)a [@pone.0080633-Unni2]                                                                   Loweing                                                                                  59.4; Asthma:                                                                            sectional                                                                                                                        Reasons Scale (4 types of                                                                                                     Concerns (5)            0.265    \<0.001
                                                                                               Medication or                                                                                   48.7                                                                                                                                                                                                                    non-adherence for each                                                                                                      Necessity (5)           1.714     0.004
                                                                                  Asthma Maintenance Medication Patients                                                                                                                                                                                                                                                                                       medication combined into any or none)                                                                                               Concerns (5)            0.506    \<0.001
  Unni & Farris                                                          USA                   Older Adults                 1061    45.6%                                                    Adherent:                                                                               Cross-                                                                                                                            4-item MMAS 1) time 1;                                                                                                      Necessity (5)           1.010     0.931
  (2011)b [@pone.0080633-Unni1]                                                                                                                                                             73.2 (9.2)                                                                              sectional                                                                                                                                2\) time 2                                                                                                            Concerns (5)            0.462    \<0.001
                                                                                                                                                                                           Non-adherent:                                                                            (two time                                                                                                                                                                                                                                                      Necessity (5)           1.075     0.560
                                                                                                                                                                                            72.5 (5.5)                                                                               points)                                                                                                                                                                                                                                                       Concerns (5)            0.503    \<0.001
  Uusküla et al.                                                         EST                        HIV                     161      55%                                                    ≤30 N = 45                                                                               Cross-                                                                                                                           Recall of proportion of                                                                                                      Necessity (6)           1.516     0.442
  \(2012\) [@pone.0080633-Uuskla1]                                                                                                                                                          \>30 N = 82                                                                             sectional                                                                                                             total doses prescribed taken during past 3 days                                                                                          Concerns (7)            0.250     0.073
  Van den Bemt                                                           NTL                    Rheumatoid                  228      33%                                                    56.2 (12.2)                                                                              Cross-                                                                                                                                 Self-report                                                                                                            Necessity (5)           1.516     0.442
  et al. (2009) [@pone.0080633-vandenBemt2], [@pone.0080633-Voils1]                              Arthritis                                                                                                                                                                          sectional                                                                                                                                                                                                                                                      Concerns (5)            0.392    \<0.001
  Voils et al.                                                           USA                   Hypertension                 201      86%                                                    64.1 (11.0)                                                                              Cross-                                                                                                                                 8-item MMAS                                                                                                            Necessity (5)           1.516     0.442
  \(2012\) [@pone.0080633-Voils1]                                                                                                                                                                                                                                                   sectional                                                                                                                                                                                                                                                      Concerns (5)            0.392    \<0.001
  Wileman et al.                                                          UK                     End-Stage                   76     60.5%                                                   63.1 (15.4)                                                                              Cross-                                                                                                                            Medications adherence                                                                                                       Necessity (5)           1.641     0.270
  \(2011\) [@pone.0080633-Wileman1]                                                            Renal Disease                                                                                                                                                                        sectional                                                                                                      quesionnaire (MAQ) plus serum phosphate level \> = 1.8 mmol/l                                                                                   Concerns (5)            0.750     0.521
  Wong &                                                                  UK                    Rheumatoid                   68      40%                                                    55.8 (13.0)                                                                           Longitudinal                                                                                                                         Patient report of drug                                                                                                      Necessity (5)           1.319     0.568
  Mulherin (2007) [@pone.0080633-Wong1]                                                          Arthritis                                                                                                                                                                                                                                                                                 continuation at 1 year versus discontinuation[b](#nt103){ref-type="table-fn"}                                                                           Concerns (5)            0.870     0.774
  Yu et al.                                                              SGP                    Peritoneal                   20      60%                                                    64.4 (11.6)                                                                              Cross-                                                                                                                          Specially designed 5 item                                                                                                     Necessity (5)           1.828     0.499
  \(2012\) [@pone.0080633-Yu1]                                                                   Dialysis                                                                                                                                                                           sectional                                                                                  scale with 5 non-adherent behaviours, rated on 5 point Likert scale plus serum phosphate \>1.78 mmol/l                                                              Concerns (5)            0.913     0.918
  Zerah et al.                                                           FRA                  Patients taking               182      21%                                                     Median 47                                                                               Cross-                                                                                                                                 4-item MMAS                                                                                                            Necessity (5)           2.008     0.042
  \(2012\) [@pone.0080633-Zerah1]                                                             Glucocorticoids                                                                            \[range 33--61\]                                                                           sectional                                                                                                                                                                                                                                                      Concerns (5)            0.484     0.035

*Note.* NZ = New Zealand; IRE = Ireland; NTL = Netherlands; CAN = Canada; FRA = France; SWE = Sweden; IRN = Iran; SWZ = Switzerland; ESP = Spain; DMK = Denmark; EGT = Egypt; SGP = Singapore; JPN = Japan; EST = Estonia; GMY = Germany; AUS = Australia; IBD = inflammatory bowel disorder; TIA = Transient Ischemic Attack; MARS is the Medication Adherence Rating Scale from Thompson, Kulkarni, & Sergejew (2000); MEMS is Medication Event Monitoring System; CQ-R is the Compliance Questionnaire-Rheumatology from de Klerk, van der Heijde, Landewé, van der Tempel, & van der Linden (2003); MMAS is the Morisky Medication Adherence Scale from Morisky, Green, & Levine (1986); TxEQ is the Transplant Effects Questionnaire from Ziegelmann et al. (2002); ACTG is the Adherence to Combination Therapy Guide from Chesney et al., 2000; RAM is the Reported Adherence to Medication Scale from Horne et al., (1999), renamed MARS (Medication Adherence Report Scale); VAS = visual analogue scale.

Adherence result selected for use in meta-analysis;

Adherence measure dichotomised into adherent and nonadherent groups;

Relationship between adherence measure and BMQ scales not reported.

Data Extraction {#s2d}
---------------

The following information was extracted from papers onto coding forms: author names, date of publication, the country in which the research was conducted (dichotomized into UK or non-UK), sample size, illness group, sex (% male), mean age, study design (cross-sectional, longitudinal or prospective), the number of Necessity and Concerns items included (since items may be added specific to the medication prescribed), the adherence measure used, information (means and standard deviations, odds ratios and 95% confidence intervals or correlation coefficients) to calculate the effect size between adherence and Necessity beliefs and Concerns, and the p-value. Where the full required statistics were not reported, authors were contacted for further information.

Methodology/Quality Assessment {#s2e}
------------------------------

A simple methodology assessment tool was devised for this study. Methodology was assessed by two of three independent expert raters (SC, RP and VC) using the following parameters:

1.  study location (UK or non-UK)

2.  study design (cross-sectional or longitudinal/prospective)

3.  measure of adherence (self-report or objective measure \[electronic monitors, prescription redemption, blood test results\]).

4.  sample size (\<82 = 0 or ≥82 = 1). This was based on the sample needed to detect a medium effect size for a correlation (*r* = 0.3) with an alpha level of 0.05 and 80% power.

Ratings were completed independently and then combined. There were no disagreements regarding ratings.

Statistical Analysis {#s2f}
--------------------

The primary outcome measure was adherence to medication. For each study, the effect size was expressed as an odds ratio with 95% confidence intervals. Where studies reported the standard mean difference or correlation coefficient, the effect size was converted into an odds ratio, using the Comprehensive Meta-Analysis program. We used a random effects model to accommodate heterogeneity between studies which was anticipated due to differences with respect to sample characteristics, study design and the adherence measure used.

The presence of significant heterogeneity across studies was examined using the chi-squared statistic (*Q*). The magnitude of this heterogeneity across studies was estimated using the *I* ^2^ statistic [@pone.0080633-Higgins1], which assesses the percentage of variance among studies which is not due to chance.

Sensitivity analyses were conducted to ascertain whether the effect sizes seen were robust when individual studies, or studies grouped based on the methodological factors described above were excluded.

Orwin's fail-safe *N* [@pone.0080633-Orwin1], [@pone.0080633-Rosenthal1] was calculated to estimate the number of unpublished studies necessary to reverse any conclusion that a significant effect exists (based on the conservative assumption that unpublished studies would have effect sizes of equal magnitude but opposite direction to the overall effect size in this meta-analysis). Egger's t-test and funnel plots were also used to test for publication bias, in line with recent recommendations [@pone.0080633-Sterne1].

Results {#s3}
=======

Selection of Studies {#s3a}
--------------------

Ninety-four percent (3554) of the 3775 studies retrieved were rejected after checking the titles and abstracts against the selection criteria above ([Figure 1](#pone-0080633-g001){ref-type="fig"}). 223 relevant articles were identified. A search of the reference lists of these articles revealed one further relevant study [@pone.0080633-Magadza1].

![Selection process for study inclusion.](pone.0080633.g001){#pone-0080633-g001}

Of the 223 studies identified, a further 129 were excluded ([Figure 1](#pone-0080633-g001){ref-type="fig"}). Thirty of these were unpublished studies and conference proceedings. These were investigated further and authors were contacted where necessary to clarify whether unpublished work had led to publications [@pone.0080633-Aburuz1]--[@pone.0080633-Wade1]. Sixteen studies [@pone.0080633-Stafkey1], [@pone.0080633-Rajpura1]--[@pone.0080633-Harrold1] [@pone.0080633-Sud1] had since been published, fifteen of which already formed part of the included list and one additional eligible study was available online early [@pone.0080633-Rajpura2]. Six papers reported data on samples which overlapped with included studies [@pone.0080633-Edmondson1]--[@pone.0080633-McHorney1], and four were protocols for ongoing studies [@pone.0080633-LopezTorres1]--[@pone.0080633-Timmers2].

Thirteen studies were excluded because they did not include a measure of medication adherence [@pone.0080633-Gill1]--[@pone.0080633-Gadkari2]. Two of these included separate assessment modes for intentional and unintentional adherence but no overall adherence assessment [@pone.0080633-Wray1], [@pone.0080633-Gadkari2]. Fifty-five studies did not use the BMQ Specific scales [@pone.0080633-Burra1]--[@pone.0080633-Webb1]. Four studies were excluded because the relationship between treatment beliefs and adherence behaviour was not reported [@pone.0080633-Horne7], [@pone.0080633-Higgins2]--[@pone.0080633-Theunissen1]. Two articles were conducted in acute rather than long-term condition samples (influenza [@pone.0080633-Bekker1] and antibiotic use [@pone.0080633-Lam1]) and one article was excluded because *parental* beliefs about medicine were measured [@pone.0080633-Conn1]. Thirteen studies study met the inclusion criteria but the article did not contain the required statistical information. We contacted the authors but were unable to obtain the relevant data [@pone.0080633-Magadza1], [@pone.0080633-Bane1]--[@pone.0080633-vandenBemt1]. Thus, once screened against the inclusion criteria, 94 articles were retained for inclusion in the meta-analysis. [Table 1](#pone-0080633-t001){ref-type="table"} provides a summary of each of the studies included in the meta-analysis.

Three of the included studies [@pone.0080633-Byer1], [@pone.0080633-Ross1], [@pone.0080633-Brown1] reported associations between adherence and Necessity beliefs, but not Concerns. The authors of these articles were contacted, but the data for Concerns was unavailable. Two studies [@pone.0080633-Trachtenberg1], [@pone.0080633-Unni2] reported two largely non-overlapping samples for both Necessity beliefs and Concerns. Thus, data for 91 studies and 93 comparisons for Concerns, and data for 94 studies and 96 comparisons for Necessity beliefs, were included in the meta-analysis.

Sample Characteristics {#s3b}
----------------------

The mean age of participants in the 94 included studies ranged from 24.0 to 74.2, with an overall mean age of 55.8 (it was not possible to calculate the mean age in 13 studies). The percentage of males ranged from 0--100% (breast cancer and haemophilia samples respectively), with an overall percentage of males of 49.7% male (excluding 3 studies where it was not possible to calculate the number of males). Sample sizes ranged from 16 to 1871.

The total sample, *N* = 25,072, encompassed patients with asthma, renal disease, organ transplantation, dialysis chronic pain, kidney transplantation, cancer, cardiovascular disorders, Marfan's syndrome, depression, haemophilia, diabetes, HIV, rheumatoid arthritis, osteoporosis, thalassemia, inflammatory bowel disease, bipolar disorder, schizophrenia, epilepsy, migraine, back problems, glaucoma and mixed chronic illness.

Thirty-three studies (35.1%) used the MARS to measure adherence, 20 used the Morisky Medication Adherence Scale (21.2%), 3 used pharmacy refill (3.2%), 3 used electronic monitoring (3.2%) and two or fewer studies used the remaining measures.

Effect Sizes {#s3c}
------------

### Necessity beliefs {#s3c1}

There was a significant relationship between Necessity beliefs and adherence, *OR* = 1.742, 95% CI \[1.569, 1.934\], *p*\<0.0001. There was significant heterogeneity between the 96 comparisons from 94 studies, *Q*(95) = 422.662, *p*\<0.001, which was substantial in magnitude, *I* ^2^ = 77.52%.

[Figure 2](#pone-0080633-g002){ref-type="fig"} presents the individual effect-size estimates and shows that the relationship between Necessity beliefs and adherence was significant (*p*\<0.05) for 49 (51.0%) of the included studies. Sensitivity analyses revealed that the overall result was not affected when any single finding was omitted.

![Forest plot of effect sizes for BMQ Necessity and medication adherence.](pone.0080633.g002){#pone-0080633-g002}

### Concerns {#s3c2}

There was a significant relationship between Concerns and adherence and fewer Concerns about adverse effects, *OR* = 0.502, 95% CI: \[0.450, 0.560\], *p*\<0.0001. There was significant heterogeneity among the 93 comparisons from 91 studies, *Q*(92) = 481.84, *p*\<0.001, suggesting that factors other than chance accounted for a moderate-substantial amount of variance, *I* ^2^ = 80.91%.

[Figure 3](#pone-0080633-g003){ref-type="fig"} presents the individual effect-size estimates and shows that the relationship between concerns and adherence was significant (*p*\<0.05) for 53 (57.0%) of the included studies. Sensitivity analyses revealed that the overall result did not change when any single finding was omitted.

![Forest plot of effect sizes for BMQ Concerns and medication adherence.](pone.0080633.g003){#pone-0080633-g003}

Stratification by Long-Term Condition and Measurement {#s3d}
-----------------------------------------------------

See [Tables 2](#pone-0080633-t002){ref-type="table"} and [3](#pone-0080633-t003){ref-type="table"} for OR stratified by different long-term conditions and adherence measures. Two few studies reported data on the majority of conditions and measures to allow statistical tests for heterogeneity.

10.1371/journal.pone.0080633.t002

###### Analyses Stratified By Long-Term Condition.

![](pone.0080633.t002){#pone-0080633-t002-2}

                                        *[k]{.ul}*   *[OR]{.ul}*   [(95% CI)]{.ul}   *[p]{.ul}*
  ------------------------------------ ------------ ------------- ----------------- ------------
  [Necessity]{.ul}                                                                  
  Asthma                                    7           2.610       1.802--3.780      \<0.001
  Bipolar disorder                          2           1.624       0.739--3.567       0.227
  Blood disorders                           3           1.512       0.580--3.944       0.398
  Cancer                                    2           2.313       1.190--4.496       0.013
  Depression                                8           1.989       1.382--2.862      \<0.001
  Diabetes                                  6           1.502       0.930--2.425       0.096
  Dialysis/end stage renal disease          3           1.454       0.771--2.742       0.247
  Epilepsy                                  2           0.859       0.284--2.602       0.789
  Glaucoma                                  3           1.697       0.976--2.949       0.061
  High cholesterol                          2           1.497       0.659--3.401       0.335
  HIV                                       9           1.742       1.242--2.444       0.001
  Hypertension                              7           1.426       0.980--2.075       0.064
  IBD                                       3           1.775       1.560--2.020      \<0.001
  Mixed sample                              11          1.504       1.249--1.810      \<0.001
  Organ transplant                          5           2.875       1.561--5.294       0.001
  Pain                                      2           1.239       0.468--3.280       0.666
  Rheumatoid arthritis                      5           3.277       1.106--9.708       0.032
  Schizophrenia                             2           3.301       1.115--9.777       0.031
  Stroke/CHD/acute coronary syndrome        9           1.402       1.022--1.924       0.036
  [Concerns]{.ul}                                                                   
  Asthma                                    6           0.406       0.304--0.541      \<0.001
  Bipolar disorder                          2           0.410       0.250--0.672      \<0.001
  Blood disorders                           3           0.764       0.545--1.073       0.121
  Cancer                                    2           0.771       0.411--1.445       0.417
  Depression                                8           0.408       0.215--0.772       0.006
  Diabetes                                  6           0.450       0.202--1.003       0.051
  Dialysis/end stage renal disease          3           0.509       0.211--1.232       0.134
  Epilepsy                                  2           0.662       0.327--1.339       0.251
  Glaucoma                                  3           0.909       0.258--3.204       0.882
  High cholesterol                          2           0.598       0.123--2.918       0.525
  HIV                                       9           0.619       0.465--0.824       0.001
  Hypertension                              6           0.433       0.340--0.552      \<0.001
  IBD                                       3           0.612       0.536--0.698      \<0.001
  Mixed sample                              11          0.423       0.339--0.501      \<0.001
  Organ transplant                          4           0.486       0.356--0.503      \<0.001
  Pain                                      2           0.620       0.428--0.897       0.011
  Rheumatoid arthritis                      5           0.608       0.385--0.962       0.033
  Schizophrenia                             2           0.648       0.410--1.025       0.063
  Stroke/CHD/acute coronary syndrome        9           0.518       0.382--0.704      \<0.001

*Note.* CHD = coronary heart disease.

10.1371/journal.pone.0080633.t003

###### Analyses Stratified by Adherence Measure.

![](pone.0080633.t003){#pone-0080633-t003-3}

                                    *[k]{.ul}*   *[OR]{.ul}*   [(95% CI)]{.ul}   *[p]{.ul}*
  -------------------------------- ------------ ------------- ----------------- ------------
  [Necessity]{.ul}                                                              
  Brief Medication Questionnaire        2           2.350       1.122--4.341       0.022
  CQ-R                                  2          18.327       5.696--58.967     \<0.001
  Electronic monitoring                 3           1.625       0.599--4.412       0.340
  MARS                                  33          1.838       1.581--2.137      \<0.001
  MASRI                                 2           2.048       1.390--3.018      \<0.001
  MMAS                                  20          1.558       1.305--1.862      \<0.001
  Pharmacy refill                       3           1.668       0.684--4.066       0.260
  [Concerns]{.ul}                                                               
  Brief Medication Questionnaire        2           0.415       0.131--1.321       0.137
  CQ-R                                  2           0.546       0.286--1.044       0.067
  Electronic monitoring                 3           0.620       0.403--0.946       0.027
  MARS                                  31          0.425       0.362--0.500      \<0.001
  MASRI                                 2           0.410       0.251--0.669      \<0.001
  MMAS                                  20          0.590       0.426--0.817       0.002
  Pharmacy refill                       3           0.785       0.630--0.979       0.031

*Note*. CQ-R = Compliance Questionnaire- Rheumatology from de Klerk, van der Heijde, Landewé, van der Tempel, & van der Linden (2003), MARS = Medication Adherence Report Scale Scale from Horne et al., (1999), MASRI = Medication Adherence Self-Report Index from Walsh et al., 2002, MMAS = Morisky Medication Adherence Scale from Morisky, Green, & Levine (1986).

Methodology/Quality Assessment {#s3e}
------------------------------

See [Table 4](#pone-0080633-t004){ref-type="table"} for sensitivity analyses.

10.1371/journal.pone.0080633.t004

###### Analyses Stratified By Adherence Measure, Study Location, Design and Power.

![](pone.0080633.t004){#pone-0080633-t004-4}

                                  *[k]{.ul}*   *[OR]{.ul}*   [(95% CI)]{.ul}   *[p]{.ul}*   [*I*^2^]{.ul}   [Heterogeneity test]{.ul}
  ------------------------------ ------------ ------------- ----------------- ------------ --------------- ----------------------------
  [Necessity]{.ul}                                                                                         
  UK study                            32          2.201       1.786--2.713      \<0.001     72.72%\*\*\*     *Q*(1) = 7.67, *p*\<0.05
  Non-UK study                        64          1.573       1.405--1.761      \<0.001     74.79%\*\*\*   
  [Concerns]{.ul}                                                                                          
  UK study                            31          0.403       0.335--0.485      \<0.001     62.75%\*\*\*     *Q*(1) = 7.61, *p*\<0.05
  Non-UK study                        62          0.555       0.486--0.635      \<0.001     82.48%\*\*\*   
  [Necessity]{.ul}                                                                                         
  Subjective adherence measure        83          1.737       1.565--1.929      \<0.001     75.54%\*\*\*    *Q*(1) = 0.031, *p* = 0.86
  Objective adherence measure         13          1.817       1.114--2.963       0.017      86.20%\*\*\*   
  [Concerns]{.ul}                                                                                          
  Subjective adherence measure        81          0.485       0.429--0.549      \<0.001     82.84%\*\*\*    *Q*(1) = 13.55, *p*\<0.001
  Objective adherence measure         12          0.726       0.609--0.866      \<0.001         8.93%      
  [Necessity]{.ul}                                                                                         
  Prospective/longitudinal            18          1.526       1.243--1.874      \<0.001      63.02\*\*\*    *Q*(1) = 1.82, *p* = 0.18
  Cross-sectional                     78          1.798       1.595--2.027      \<0.001     79.49%\*\*\*   
  [Concerns]{.ul}                                                                                          
  Prospective/longitudinal            18          0.449       0.356--0.567      \<0.001     70.88%\*\*\*    *Q*(1) = 1.14, *p* = 0.29
  Cross-sectional                     75          0.519       0.458--0.588      \<0.001     81.28%\*\*\*   
  [Necessity]{.ul}                                                                                         
  Low power                           18          1.848       1.290--2.646       0.001        46.19%\*      *Q*(1) = 0.12, *p* = 0.73
  High power                          78          1.730       1.550--1.930      \<0.001      80.16\*\*\*   
  [Concerns]{.ul}                                                                                          
  Low power                           17          0.488       0.371--0.643      \<0.001         0.00%       *Q*(1) = 0.05, *p* = 0.82
  High power                          76          0.505       0.448--0.570      \<0.001     83.83%\*\*\*   

Note. \*p\<.05, \*\*\*p\<.001 for Q statistic.

### Study location {#s3e1}

Most studies were conducted outside of the UK (*n* = 62; 66.0%). Stronger effects were apparent for both Necessity and Concerns for studies conducted in the UK relative to studies conducted outside of the UK, however the relationship between Necessity and Concerns was significant for both locations. Substantial and significant heterogeneity was present in all analyses.

### Study design {#s3e2}

The majority of studies (*n* = 77, 81.9%) were cross-sectional, with few studies using longitudinal or prospective designs (*n* = 17; 18.1%). Effect sizes were similar for longitudinal/prospective and cross-sectional designs for both Necessity and Concerns. Substanital and signficant heterogeneity was present in all analyses.

### Measurement of adherence {#s3e3}

Eighty-three studies (88.3%) employed measured adherence using self-report, while 11 (11.7%) used other methods. The association between adherence and Concerns was smaller, but still significant, when objective measures were used, and the heterogeneity around this estimate was small. The association between Necessity beliefs and adherence did not differ if objective or subjective adherence measures were used. Heterogeneity around the subjective measures estimates and the objective Necessity estimate was substantial.

### Statistical power {#s3e4}

Eighteen (19.1%) of the studies were classed as having small samples (less than 82). The size of the associations between Necessity and Concerns and adherence were similar for smaller and larger studies. Heterogeneity estimates indicated that variability around the larger samples estimates was substantial. However, the smaller sample estimates were less heterogeneous, with I^2^ values in the small range for Concerns and the moderate range for Necessity beliefs.

Assessment of Risk of Publication Bias {#s3f}
--------------------------------------

### Necessity {#s3f1}

The fail-safe *N* (*N~fs~*) was 96, indicating that there would need to be ≥96 unpublished findings of an equal magnitude but opposite direction, to reverse our conclusion that a significant effect exists. Inspection of the funnel plot suggested asymmetry (see [Figure 4](#pone-0080633-g004){ref-type="fig"}), however Duval and Tweedie's trim and fill method did not suggest that studies should be added/removed. Egger's t-test was significant, *t*(94) = 1.60, *p*\<0.001, suggesting the presence of asymmetry.

![Funnel plot for BMQ Necessity and medication adherence.](pone.0080633.g004){#pone-0080633-g004}

### Concerns {#s3f2}

The fail-safe *N* (*N~fs~*) was 94, indicating that there would need to be ≥94 unpublished findings of an equal magnitude but opposite direction, to reverse our conclusion that a significant effect exists. Funnel plot inspection suggested the presence of asymmetry (see [Figure 5](#pone-0080633-g005){ref-type="fig"}), which was confirmed by a significant Egger's t-test, *t*(91) = 1.80, *p*\<0.001. Further, Duval and Tweedie's trim and fill method suggested 13 studies should be added/removed to make the funnel plot symmetrical. The location of the imputed studies indicated that the asymmetry may arise from a lack of reporting of studies which find a negative relationship between concerns and adherence. However, the similarity between the adjusted *OR* 0.567 95% CI \[0.507, 0.634\], which includes the imputed trimmed and filled studies, and the observed *OR* 0.504 95% CI \[0.450, 0.564\], suggests that any bias does not have a large impact on the findings.

![Funnel plot for BMQ Concerns and medication adherence.](pone.0080633.g005){#pone-0080633-g005}

Discussion {#s4}
==========

This meta-analytic review indicates that the Necessity-Concerns Framework (NCF) is a potentially useful model for understanding patients' evaluations of prescribed medicines. The magnitude of the aggregate effect sizes indicates that, for each standard deviation increase in Necessity beliefs, the odds of adherence increases by a factor of 1.7. Conversely, for each standard deviation increase in Concerns, the odds of adherence decreases by a factor of 2.0.

Strengths and Limitations of the Study {#s4a}
--------------------------------------

The sensitivity and publication bias analyses conducted confirm our hypothesis that Necessity beliefs and Concerns are associated with adherence/nonadherence to medicines, across a wide range of conditions, medications, and study locations. No research synthesis can transcend the limitations of the primary studies. However, sensitivity analyses confirmed that this association is robust across methodological features; remaining when small, underpowered studies were removed, when only longitudinal/prospective designs were included, and when self-report and non self-report adherence assessments were included separately. The majority of the studies relied solely on self-reported adherence. Self-report measures have high face validity and high specificity for nonadherence, however they may be subject to self-presentation and recall bias [@pone.0080633-Garfield1]. Thus some people may be reporting higher adherence rates than they actually attain. This bias does not diminish our confidence in the finding that beliefs were related to adherence, as there is no evidence that such a bias would be associated with medication beliefs. Indeed some patients with high Concerns and low Necessity beliefs may be expected to incorrectly report high adherence in order to present themselves positively. This pattern would attenuate the relationship found between adherence and medication beliefs, making it less likely that we would find an association between beliefs and adherence. Moreover, given that this relationship remained when non-self report measures were used, we are confident that the observed relationships between beliefs and adherence are not an artifact arising from the limitations of self-report. Only published studies were included, creating a possible bias, since studies submitted for publication may be more likely to have positive results and larger effect sizes. Since for both Necessity beliefs and Concerns, the fail safe N indicated that the number of additional negative findings required to accept our null hypothesis was similar to the number of studies included in this meta-analysis, and there was little suggestion of publication bias through funnel plot analysis, our findings appear to reflect a true relationship between beliefs and adherence.

Stratifying by long-term condition and adherence measurement revealed a need for further studies using objective measures, and highlighted some conditions, for example epilepsy and functional pain syndromes where further research is needed. We do not know whether the Necessity-Concerns Framework will be of equal utility across medications administered by different routes e.g. depot injections, or if practical barriers to care may be of relatively greater importance in some groups using medications administered through different routes.

Eighteen studies assessed whether Concerns and Necessity beliefs could predict adherence using longitudinal/prospective designs. The relationship was not reduced in these studies, supporting the proposal that medication beliefs can influence later adherence as part of the self-regulation of illness [@pone.0080633-Horne6]. We did not restrict our inclusion criteria to studies published in English. However, our search only identified one study published in any other language, despite the fact that the BMQ was translated into the native language for the study. Cultural values [@pone.0080633-Hofstede1] can impact on the way in which individuals interact with the healthcare system. However, variations in treatment necessity and concerns and association between these beliefs and adherence were noted across different countries, languages and cultures. We found that studies outside the UK, where the BMQ and it's disease-specific modifications have been predominantly developed, found reduced associations between necessity and concerns beliefs and adherence. Further work is needed to investigate potential cultural variations in medication beliefs.

Implications for Research and Practice {#s4b}
--------------------------------------

The development of more effective methods for addressing nonadherence is a priority for research and practice [@pone.0080633-National1], [@pone.0080633-Haynes1]. Our findings suggest, that novel interventions to support informed choice and optimal adherence to appropriately prescribed medicines are likely to be more effective if they take account of patients' beleifs about the treatment and how they judge their personal need for the prescription relative to concerns about ponteial adfverse consequences of taking it. Necessity beliefs and Concerns may trigger intentional nonadherence, for example, if patients decide not to take their medication due to concerns regarding potential or actual adverse consequences, and unintentional nonadherence, (e.g. if patients who believe a medicine is not important for their health forget to take it). Beliefs can have counter-balancing effects on adherence, such as when patients continue to take a medication they believe is essential for their health despite concerns regarding adverse effects ^15^. The challenge now is to develop effective interventions to address patients' doubts about the necessity for treatment and concerns about adverse consequences in order to enhance adherence. The challenge goes beyond 'getting patients to take more medicines'. Our findings show that many patients harbour significant, unresolved doubts and concerns about prescribed treatment suggesting a fault-line between patients' and prescribers' cultural perceptions of the treatment. Viewed from the perspective of biomedicine, nonadherence may seem irrational. However, from the patients' perspective, nonadherence may be a 'common-sense' response to their implicit appraisal of the treatment. For some patients nonadherence might represent an *informed* choice. In this case the outcome of 'adherence support' would be to avoid prescribing an unwanted treatment, to the relief of patient and payer. However, for others, evaluations of treatment necessity and concerns may be based on misconceptions about the illness and treatment.

More detailed studies of patient representations illness and treatment show that, even when treatment evaluations are based on misconceptions they appear to draw on a 'common-sense' logic [@pone.0080633-Horne4], [@pone.0080633-Leventhal1], [@pone.0080633-Kleinman1]. For example, the need for daily medication may seem less salient when symptoms are absent or cyclical [@pone.0080633-Halm1]--[@pone.0080633-Horne12]. Concerns about prescribed medication are not just related to side effects but are common, even when the medication is well tolerated. They are often related to beliefs about the negative effects of medication and include worries about long-term effects, dependence, cost of medication and dislike of having to rely on medicines [@pone.0080633-Horne6], [@pone.0080633-Horne12]. Concerns are related to more general beliefs about pharmaceuticals as a class of treatment which are often perceived as intrinsically harmful and over-prescribed by doctors [@pone.0080633-Horne12], [@pone.0080633-Calnan1]. The package information leaflets, dispensed with many prescription medicines may exacerbate concerns as they list all possible side effects, leaving patients with outstanding questions and making it difficult to understand the likely risk and place them in context with potential benefits [@pone.0080633-Bowskill1].

Nonadherence is often a hidden problem. Patients may be reluctant to express doubts or concerns about prescribed medication and to report nonadherence; sometimes because they fear that this will be perceived by the prescriber as a lack of faith in them. The first step to facilitating adherence is therefore to take a 'no-blame approach' and encourages an honest and open discussion to identify nonadherence and the reasons for nonadherence [@pone.0080633-National1]. Adherence support should be tailored to the needs of the individual addressing perceptions (e.g. necessity beliefs and concerns) as well as practicalities (e.g. capacity and resources). This can be approached in a three stage process: 1) communicating a common-sense rationale for personal need that takes account of the patient's perceptions of the illness and symptoms expectations and experiences 2) eliciting and addressing specific concerns and 3) making the treatment as convenient and as easy to use a possible. Interventions attempting to improve adherence by applying these approaches have had encouraging results [@pone.0080633-Clifford1], [@pone.0080633-Elliott1]. Nonadherence remains a fault-line in clinical practice. Consideration of patients' perceptions of treatment necessity and concerns in prescribing and treatment review is essential to support informed choice and optimal adherence to appropriately prescribed treatment.
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